Givinostat is a potentially life-altering drug for children with Duchenne muscular dystrophy. The European Commission granted conditional marketing authorisation for givinostat almost a year ago, on 6 June 2025. There has been a frustrating delay, some of it on the company's behalf. I understand that the HSE's drugs group will review givinostat at its June meeting and make a recommendation to the senior leadership team to approve the medicine or not. There is a campaign, Time is Muscle. Every day counts for these children. I ask that a decision be made as early as possible. Children need access to this drug.

Sentiment score: -0.05